hyperCORE International Appoints Nicholas Focil as New President
Nicholas Focil's appointment as president of hyperCORE International signals a strategic move to enhance the network's global clinical research impact through his extensive experience in clinical operations and diversity in trials.
hyperCORE International has announced Nicholas Focil as its new president, bringing nearly two decades of clinical operations leadership to the role. Focil, founder and CEO of FOMAT Medical Research, is recognized for his work in expanding clinical trials into emerging markets and promoting diversity in research. His appointment is expected to further hyperCORE's mission of conducting ethical, high-quality clinical trials across its extensive network.
Focil succeeds Carlos Orantes, whose leadership has been pivotal in hyperCORE's growth. Orantes expressed confidence in Focil's ability to continue the network's path of excellence. Focil acknowledged Orantes's contributions and the legacy of previous presidents, emphasizing his commitment to advancing hyperCORE's operational excellence and patient-centered care.
Under Focil's presidency, hyperCORE aims to enhance site capabilities, expand trial reach, and deliver diverse, high-quality research. This leadership transition comes at a time of significant growth for hyperCORE and the clinical research industry at large, highlighting the network's role in advancing global health through innovative and inclusive clinical trials.